Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is frequently in the news as a global company focused on pet healthcare innovation, veterinary diagnostics, and software. News about IDEXX often highlights product launches, diagnostic advances, financial results, and corporate governance updates, reflecting its role in companion animal care, livestock and dairy health, and water safety.
Recent announcements include new diagnostic imaging and cancer testing capabilities. IDEXX has introduced the Vue DR50 Plus Digital Imaging System, described as its most advanced diagnostic imaging solution for veterinary practices, combining high-definition, AI-powered imaging with lower radiation doses compared with earlier IDEXX systems and other veterinary imaging solutions. The company has also reported expansions of its IDEXX Cancer Dx Panel and applications on the inVue Dx Cellular Analyzer, aimed at providing earlier insights and rapid, in-clinic answers for canine cancer cases.
Investors and veterinary professionals following IDXX news will also encounter quarterly earnings releases, where IDEXX discusses revenue growth, earnings per share, and performance across areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Additional news items cover topics like CEO succession planning, board appointments, and participation in investor conferences.
This news page aggregates these types of updates so readers can review IDEXX’s latest disclosures on diagnostics, software, AI-enabled tools, telemedicine services, and financial performance. For anyone tracking IDXX stock, veterinary sector developments, or advances in animal health diagnostics, this feed provides a centralized view of the company’s publicly reported developments over time.
PetDx has announced a collaboration with IDEXX Laboratories to enhance access to its liquid biopsy test for canine cancer, OncoK9. This test, which allows for noninvasive cancer detection through a simple blood draw, will be available to veterinary customers in the U.S. and Canada by the end of January 2022. OncoK9 utilizes advanced genomic analysis and sequencing technology, showing promising results in clinical studies. With an estimated six million new canine cancer diagnoses annually, this collaboration aims to improve diagnostics and care for dogs suffering from cancer.
IDEXX Laboratories (NASDAQ: IDXX) announced enhancements to its products and services aimed at improving veterinary practices' efficiency amidst rising patient volumes. Key enhancements include clinical decision support for the IDEXX 4Dx® Plus Test, improvements to the VetConnect® PLUS Mobile App, advanced software for the SediVue Dx® Urine Sediment Analyzer, and a new Catalyst® SDMA Test to streamline workflows. These innovations are designed to aid veterinarians in making quicker, confident clinical decisions, reflecting IDEXX's commitment to supporting the growing demands of veterinary professionals.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced the expansion of its reference laboratory tests to improve cancer diagnosis and treatment for veterinarians. This new offering includes a liquid biopsy test using DNA sequencing for common canine cancers, a diagnostic panel for identifying genetic mutations, and innovative diagnostic profiles for therapy management. With around 6 million new cancer diagnoses annually in dogs and cats in the U.S., IDEXX aims to support veterinarians in managing complex cancer cases more effectively.
IDEXX Laboratories (NASDAQ: IDXX) will announce its 2021 fourth quarter and full year financial results on February 2, 2022, before market opening. An analyst conference call will follow at 8:30 a.m. ET, accessible via a live webcast on the IDEXX website. This event will also be available by telephone, requiring an access code. IDEXX specializes in veterinary diagnostics and practice software, operating globally with around 9,800 employees. The company is a member of the S&P 500 Index, providing innovative solutions to veterinarians and ensuring quality in water and food safety.
IDEXX Laboratories reported a 12% revenue growth for Q3 2021, reaching $810 million. The Companion Animal Group (CAG) Diagnostics saw significant contributions with a 13% increase in recurring revenue. Earnings per share (EPS) stood at $2.03, marking a 20% growth. IDEXX updated its 2021 guidance, projecting revenue growth between 17.5% - 18% and EPS growth of 24% - 25%. CAG capital instrument revenues surged 34%. However, Livestock, Poultry, and Dairy (LPD) revenues declined 21% as compared to last year.
IDEXX Laboratories, a leader in veterinary diagnostics, will announce its third quarter financial results for 2021 on November 2, 2021, before markets open. The company will host an analyst conference call at 8:30 a.m. ET on the same day. Access to the live call will be available through IDEXX's website and via telephone. IDEXX employs around 9,800 people and provides diagnostics and software for veterinary, livestock, and water quality sectors, serving customers in over 175 countries.
IDEXX Laboratories (NASDAQ: IDXX) will host a virtual Investor Day on August 12, 2021, from 10:00 AM to 12:30 PM EDT. This event features presentations by senior leadership, including CEO Jay Mazelsky and CFO Brian McKeon, followed by a Q&A session. Participants can access the live webcast and slide presentations via IDEXX's investor page. An archived replay will be available shortly after the event. IDEXX is recognized for its innovative solutions in veterinary diagnostics, software, and water testing.
IDEXX Laboratories announced strong second quarter results for 2021, with a reported revenue growth of 30% and organic revenue growth of 25%. The Companion Animal Group (CAG) Diagnostics saw recurring revenue growth of 30% reported and 26% organic. The earnings per share (EPS) reached $2.34, a 36% increase. The company raised its 2021 revenue guidance to $3.170 - $3.205 billion and EPS outlook to $8.20 - $8.36. Growth drivers include strong demand for CAG Diagnostics and expansion in water testing revenues.
IDEXX Laboratories, a leading veterinary diagnostics company, will release its 2021 second quarter financial results on July 30, 2021, before market opening. The accompanying analyst conference call is scheduled for 8:30 a.m. ET on the same day. Interested parties can access a live webcast at www.idexx.com/investors or join via telephone by dialing 1-888-771-4371 or 1-847-585-4405 with access code 50183464. An archived version of the call will be available after 1:00 p.m. ET and remain accessible for one year.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has acquired ezyVet®, a leading cloud-based practice information management system. This strategic acquisition enhances IDEXX's portfolio, allowing the company to offer comprehensive cloud software solutions that improve veterinary practice efficiency and care standards. The acquisition includes Vet Radar, an innovative electronic treatment sheet solution. IDEXX aims to leverage ezyVet's technology to enhance customer satisfaction and support veterinarians in their business growth.